Abstract 1133P
Background
Metastatic uveal melanoma (MUM) is a rare and lethal disease with varied clinical course. Despite the existence of well-characterized molecular drivers none have been associated with clinical outcomes in MUM. We aimed to study how uveal melanoma genetic alterations affect MUM prognosis.
Methods
From a prospective database of MUM patients, we analysed molecular alterations of primary tumors, including mutations (GNAQ/GNA11 and SF3B1) and chromosomal imbalances (chr3 monosomy (M3),chr8q amplification (+8q), chr8p deletion (-8p),chr8p amplification (+8p), chr1p deletion (-1p), chr6p deletion (-6p), and chr6q amplification (+6q)). Relevant clinical features at the time of MUM diagnosis, such as age, sex, disease-free survival from primary tumor, ECOG score, size of liver metastasis, and levels of LDH, alkaline phosphatase (ALP), bilirubin (BIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were recorded. Survival analysis was calculated from MUM diagnosis to death or last follow-up.
Results
Molecular data was obtained from 59 of 119 MUM patients treated at our institution from 2007 to 2022. The mutational driver profile was: 46% GNAQ and 40% GNA11; 42% Q209P and 44% Q209L; 19% SF3B1 mutation being 10% R625H, and 9% R625C. Chromosomal alterations were: M3 81%, +8q 60%, +8p 15%, -8p 12%, -1p 30%, -6q 17%, and +6p 17%. The median overall survival (mOS) for the entire cohort was 16 months(m). Among all genetic alterations, only SF3B1 had a significant impact on mOS: 13m (95% CI 10-15) for wild-type (WT) vs 31.6 m (95% CI 16-46) for mutant (MUT), p=0.01, HR=0.32. Survival probability was higher at 12, 24, and 48m for WT vs MUT (57% vs 81%, 17% vs 70%, and 6% vs 37%). SF3B1 mutation was not statistically associated with any clinical variable. In the multivariate analysis using all clinical variables and SF3B1 status, only DFS ≥2y (HR=2.3), elevated LDH (HR=3.5), elevated ALP (HR=6.1), and SF3B1 MUT (HR=0.2, 95%CI 0.1-0.8, p=0.02) remained significant.
Conclusions
SF3B1 mutation is independently associated with improved OS in MUM patients. Results may affect MUM care, treatment development, and trial stratification. More research is needed to confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13